Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy
- PMID: 30555798
- PMCID: PMC6284041
- DOI: 10.3389/fonc.2018.00546
Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy
Abstract
Background: This study aims to assess the prognostic significance of radiographic numbers of positive pelvic lymph nodes (PLNs) in patients with cervical cancer treated with definitive concurrent chemoradiotherapy (CCRT) or intensity-modulated radiotherapy (IMRT). Methods: We conducted a retrospective study that included 164 eligible adult patients with cervical cancer who were treated with definitive CCRT or IMRT at our institution from 2009 to 2016. After exclusion of 50 patients, a total of 114 patients whose clinicopathological data and follow-up were finally analyzed. The radiographic numbers of positive PLNs were assessed by pretreatment magnetic resonance imaging (MRI) or computed tomography (CT). The criterion for a positive lymph node was defined as a short-axis diameter >1 cm. Using the Kaplan-Meier method and the Cox proportional hazards regression model, we assessed the overall survival (OS), cancer-specific survival (CSS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). Results: The median follow-up duration was 40 (range: 2-100) months. For patients with 0, 1-2, and ≥3 positive PLNs, the estimated 3-year OS were 85.4% vs. 82.4% vs. 59.7% (p = 0.035), CSS were 90.1% vs. 86.1% vs. 62.9% (p = 0.010), DMFS were 89.4% vs. 91.3% vs. 49.6% (p < 0.001), and LRFS were 77.8% vs. 73.4% vs. 70% (p = 0.690). Per the multivariate Cox regression, positive PLNs ≥3 (HR, 2.51; 95% CI: 1.09-5.80; p = 0.031) and non-squamous cell carcinoma type (HR, 2.82; 95% CI: 1.19-6.69; p = 0.018) were unfavorable factors for the OS. Besides, positive PLNs ≥3 was the independent factor for the CSS (HR, 3.38; 95% CI: 1.32-8.67; p = 0.011) and DMFS (HR, 6.83; 95% CI: 2.62-17.83; p < 0.001). The patients that were treated without intracavitary brachytherapy exhibited inferior LRFS (HR, 13.15; 95% CI: 2.66-65.10; p = 0.002). Conclusions: The radiographic number of positive PLNs (≥ 3) is an independent prognostic factor for OS, CSS, and DMFS in patients treated with definitive CCRT or IMRT.
Keywords: CCRT; IMRT; cervical cancer; pelvic lymph node; positive lymph nodes; radiographic finding; survival.
Figures


Similar articles
-
Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.J Cancer. 2017 Aug 23;8(14):2836-2845. doi: 10.7150/jca.19725. eCollection 2017. J Cancer. 2017. PMID: 28928873 Free PMC article.
-
The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.J Formos Med Assoc. 2015 Mar;114(3):231-7. doi: 10.1016/j.jfma.2012.10.021. Epub 2013 Jan 5. J Formos Med Assoc. 2015. PMID: 25777974
-
Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy.Bosn J Basic Med Sci. 2019 May 20;19(2):186-194. doi: 10.17305/bjbms.2019.3873. Bosn J Basic Med Sci. 2019. PMID: 30877837 Free PMC article.
-
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070. Am J Clin Oncol. 2016. PMID: 24710123
-
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.Chin J Cancer. 2016 Jan 6;35:2. doi: 10.1186/s40880-015-0076-9. Chin J Cancer. 2016. PMID: 26739148 Free PMC article.
Cited by
-
Comprehensive Analysis of the SUMO-related Signature: Implication for Diagnosis, Prognosis, and Immune Therapeutic Approaches in Cervical Cancer.Biochem Genet. 2024 Dec;62(6):4654-4678. doi: 10.1007/s10528-024-10728-2. Epub 2024 Feb 13. Biochem Genet. 2024. PMID: 38349439
-
Results from chemoradiotherapy for squamous cell cervical cancer with or without intracavitary brachytherapy.J Contemp Brachytherapy. 2019 Oct;11(5):417-422. doi: 10.5114/jcb.2019.88116. Epub 2019 Oct 30. J Contemp Brachytherapy. 2019. PMID: 31749849 Free PMC article.
-
Validation of the prognostic value of various lymph node staging systems for cervical squamous cell carcinoma following radical surgery: a single-center analysis of 3,732 patients.Ann Transl Med. 2020 Apr;8(7):485. doi: 10.21037/atm.2020.03.27. Ann Transl Med. 2020. PMID: 32395529 Free PMC article.
-
Comparison of different lymph node staging systems in patients with node-positive cervical squamous cell carcinoma following radical surgery.J Cancer. 2020 Oct 23;11(24):7339-7347. doi: 10.7150/jca.48085. eCollection 2020. J Cancer. 2020. PMID: 33193898 Free PMC article.
-
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403. Technol Cancer Res Treat. 2022. PMID: 35341413 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. (2017) 3:524–48. 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Medical